LP-184 by Starlight Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Harnessing the untapped potential of medicines access – Pharmaceutical Technology

Share this article When it comes to medicines access, numerous factors may delay or prevent medical products from reaching patients. It is the role of

January 25, 2024

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft – Biotech Investments

Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

June 26, 2024

Addressing health care workers’ trauma can help fight burnout

Burnout is a growing crisis in health care: More than 50% of health care professionals report symptoms of it. Addressing the trauma they face at

May 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.